Accueil
Envoyer à un ami
Imprimer
Grand
Petit
Partager
ACTUALITES

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including ...


- 9 Septembre 2016 modifié le 1 Janvier 1970


(BUSINESS WIRE)-- Boehringer Ingelheim today announced that the European Commission (EC) and U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).

SENSCIS™, the largest trial to date in this disease area, is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD.

Systemic sclerosis, commonly referred to as “scleroderma,” is a disfiguring, disabling and potentially fatal rare disease that can cause scarring of the skin, lungs (SSc-ILD) and other organs. Worldwide, an estimated two million people have systemic sclerosis (also known as scleroderma) and up to 90% may develop some degree of lung scarring. SSc-ILD indicates a poor prognosis and accounts for 35 percent of all disease-related deaths. ...

Source : http://me-newswire.net//news/18627/en...



ACTUALITES | INTERNATIONAL | TCHAD | POLITIQUE | CULTURE | EXCLUSIF | Revue de Presse | English News | 中國